Related Experiment Video
Updated: Aug 26, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
Published on: April 9, 2014
Antiretroviral therapy in patients with hepatitis and HIV: weighing risks and benefits
1Division of Infectious Diseases, Washington University School of Medicine, St. Louis, Missouri 63110, USA. wpowderl@im.wustl.edu
Abstract:
Liver disease is an important complication of human immunodeficiency virus (HIV) infection. As HIV-infected patients live longer, they develop long-term manifestations of chronic HIV infection and/or treatment complications. Progressive liver disease is one of the leading causes of morbidity and mortality in this patient group. Underlying hepatitis B and/or C virus infection is extremely common. All classes of antiretroviral drugs have been associated with some hepatotoxicity, and patients often receive other potentially liver-damaging drugs. Alcohol use is common and frequently underestimated. All of these issues make liver disease an important factor in making antiretroviral decisions. Clinicians should weigh underlying disease, behavioral issues such as drugs and alcohol, and concomitant therapy when choosing antiretrovirals in such patients. We need more research in this area, especially with regard to mechanisms, risks, and management--for specific drugs and regimens--to ensure that our patients receive the benefits of antiretroviral therapy in the safest manner possible.
Related Concept Videos
Retrovirus Life Cycles
Inhibitors of Viral Protein Synthesis
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Viral Hepatitis I: Introduction
Hepatitis
Antiviral Nucleoside Inhibitors

